SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep slide to fresh lows is being tied by traders to weakening Trump-related political sentiment and the approaching midterms, with some also pointing to Truth Social engagement and the companys limited operating business. The discussion is overwhelmingly bearish, though a few traders view the decline as a potential entry point or rebound setup.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention ahead of its Q3 earnings report, with traders weighing mixed options positioning and bracing for an event-driven move. Discussion centers on whether pricing and vehicle mix can offset weaker sales and steep declines in EV demand.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Interim ARO-MAPT results showing substantial tau reduction after subcutaneous dosing have renewed attention on Arrowheads potential to deliver RNAi therapies across the blood-brain barrier. Many traders view the data as important validation of the platform, while others are frustrated by the muted share-price reaction and note that the results are early biomarker data, not evidence of clinical benefit.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is drawing attention amid a sharp AI and semiconductor selloff followed by a rebound, with traders debating whether the weakness is a temporary unwind or a warning that debt-heavy data-center spending may not deliver adequate returns, particularly as CoreWeave faces credit concerns. Dip buyers point to continued GPU demand and upcoming company updates, while skeptics question the sustainability of AI infrastructure spending and Nvidias exposure to it.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious early anniversary LinkedIn post has traders speculating that major news may be near, including a REGAL trial update or a possible buyout; skeptics see it as a routine anniversary message, not a confirmed signal. Discussion centers on the blinded Phase 3 REGAL trial nearing its final-analysis trigger, with the timing and outcome still uncertain.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United is drawing attention for CEO Scott Kirbys comments backing a near-100% inheritance tax, which have prompted some traders to call for a boycott or selloff while others dismiss the remarks as separate from the stock. The debate is unfolding ahead of quarterly results, with traders also weighing the recent share-price pullback, fuel costs and whether demand and guidance can support earnings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a volatile rebound after a steep selloff in AI infrastructure and neocloud stocks, as traders weigh concerns about debt, funding needs and whether AI spending will generate adequate returns. Some see the decline as an oversold buying opportunity, while others warn that sector-wide pressure and financing risks could keep shares weak.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid a steep post-IPO selloff, with traders pointing to newly unlocked shares, insider selling, and an analyst target cut as sources of pressure, alongside concerns about OpenAI customer concentration and the companys ability to scale. Bears expect more downside, while bulls argue the decline has left the AI-chip maker oversold and emphasize its technology and long-term potential.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced full-year outlook, driven by surging fuel costs, dominate discussion. Traders are split between confidence in resilient travel demand and pricing power, and concern that fuel and other operating costs will keep squeezing margins.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons rally is drawing attention after Morgan Stanley named it a top pick and raised its outlook, citing accelerating AWS growth and AI-related demand. Traders welcomed the upgrade, while debating whether the jump can hold ahead of earnings and amid concerns about heavy capital spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GMED or AXGN: Which Is the Better Value Stock Right Now?

GMED vs. AXGN: Which Stock Is the Better Value Option?

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireVANCOUVER, BC, Oct. 3, 2026VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big...

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.read more...

Axogen To Acquire BioCircuit Technologies

(RTTNews) - Axogen (AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, a privately held medical device company and developer of NerveTape, the first FDA-approved device for sutureless nerve repair. Axogen will acquire BioCircuit for total considerat...

Axogen (AXGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology PR...

NZS Capital Added Axogen (AXGN) as an Optionality Position

NZS Capital Added Axogen (AXGN) as an Optionality Position...

Axogen, Inc. engages in the development and marketing of surgical solutions for peripheral nerve regeneration and repair. It provides products and educational resources to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Avive Soft Tissue Membrane, AcroVal Neurosensory and Motor Testing System, and AxoTouch Two-Point Discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Axogen Inc.

AXGN Stock Rises After FDA Approves Nerve Repair Graft

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves.</li><li>It eliminates the need for a secondary nerve-harvest surgery, helping lower the risk of complications and aiding faster recovery.</li><li>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026.</li></ul><p>Shares of Axogen Inc. (AXGN) were up nearly 12% in Thursday’s opening trade after the company announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its nerve repair graft.</p><p>Axogen announced on late Wednesday that the FDA had approved its Biologics License Application for Avance, which is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.</p><p>Retail sentiment on Stocktwits around the&nbsp;<a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> soared, entering the ‘extremely bullish’ territory from ‘bullish’ a day ago, while message volumes increased to hover at ‘extremely high’ levels from ‘normal’ a day ago.</p><h2 class="st-heading-2">Why Is This Important?</h2><p>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves. It eliminates the need for a secondary nerve-harvesting surgery, helping reduce the risk of complications and enabling faster recovery.</p><p>“This milestone clarifies and strengthens our regulatory footing and confirms approval for use of Avance as an acceptable therapeutic option for treating peripheral nerve discontinuities in all of Axogen’s present nerve repair use cases,” said Michael Dale, CEO, Axogen.</p><h2 class="st-heading-2">When Will It Be Available?</h2><p>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026. Until then, the company will continue to offer Avance under the current tissue framework.</p><p>Axogen cautioned that since Avance is made from human donor tissue, there is a risk of transmitting infectious agents such as viruses.</p><h2 class="st-heading-2">Who Is Avance Aimed At?</h2><p>According to the company, Avance is intended for patients older than one month. These patients may have sensory nerve discontinuity of less than or equal to 25 millimeters.</p><p>For patients with sensory nerve continuity of more than 25 mm or those with mixed and motor nerve discontinuity, Avance has received accelerated approval, according to the company. It noted that continued approval is contingent upon confirmatory clinical trial results.</p><p><a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> is up 89% year-to-date and 110% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/robotics-stocks-surge-trump-executive-order-reports/cLIXDUjRE1r"><strong>iRobot, Richtech Robotics Stocks Surge As Trump Administration Reportedly Considers Executive Order To Accelerate Development</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.

Why Is AXGN Stock Rising Today?

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$35.24
Prev Close	$34.62
Open	$34.86
Dividend Yield	0.00%
50-Day Moving Average	$44.19
Beta	0.97
Avg. Volume	1.29M
PE Ratio	-52.29

52-Week High	$52.91
52-Week Low	$16.79
Market Capitalization	$2.03B
EPS (Annual)	-$0.341
Price to Book	7.38
Revenue Per Employee	$362,070.74

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXGN Fundamentals